# 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

> **NCT01906489** · PHASE2 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 210 (actual)

## Conditions studied

- Anemia
- Chronic Kidney Disease

## Interventions

- **DRUG:** AKB-6548
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01906489
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-23
- **Primary completion:** 2014-09-03
- **Final completion:** 2014-09-03
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2022-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01906489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01906489, "20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01906489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*